SUBCLINICAL LEAFLET THROMBOSIS AND ANTICOAGULATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT

New York–Presbyterian Hospital/Columbia University Irving Medical Center

Subclinical leaflet thrombosis affects approximately 15% of patients after TAVR, with its pathophysiology and clinical significance remaining incompletely understood. Recent randomized trials have evaluated the effectiveness of oral anticoagulation (OAC) in preventing this condition. While OAC has shown efficacy in reducing leaflet thrombosis, it does not translate into a clinical benefit for patients, and in some cases, may pose risks due to bleeding. The review emphasizes the need for strategies to identify patients who would benefit from OAC while minimizing risks.